Cullen Frost Bankers Inc. Boosts Stake in Thermo Fisher Scientific Inc. $TMO

Key Points

• Cullen Frost Bankers increased its Thermo Fisher Scientific stake by 7.8% in the fourth quarter, buying 2,757 additional shares and bringing its total holdings to 38,315 shares worth about $22.2 million.
• Thermo Fisher reported better-than-expected quarterly results, with EPS of $5.44 versus estimates of $5.25 and revenue of $11.01 billion versus $10.86 billion expected. Revenue rose 6.2% year over year, and the company raised its quarterly dividend to $0.47 per share.
• Despite strong results, the stock has faced mixed sentiment: several analysts cut price targets, but the consensus rating remains “Moderate Buy.” Shares were recently trading well below their 12-month high, and insiders, including the CEO and COO, also sold stock.

Cullen Frost Bankers Inc. lifted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 7.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 38,315 shares of the medical research company's stock after purchasing an additional 2,757 shares during the quarter. Cullen Frost Bankers Inc.'s holdings in Thermo Fisher Scientific were worth $22,202,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently modified their holdings of the business. Assetmark Inc. increased its position in Thermo Fisher Scientific by 22.9% during the fourth quarter. Assetmark Inc. now owns 37,654 shares of the medical research company's stock valued at $21,819,000 after acquiring an additional 7,023 shares during the last quarter. Cornerstone Investment Partners LLC purchased a new stake in Thermo Fisher Scientific during the third quarter valued at $41,393,000. Mackenzie Financial Corp increased its position in Thermo Fisher Scientific by 29.4% during the third quarter. Mackenzie Financial Corp now owns 276,545 shares of the medical research company's stock valued at $134,130,000 after acquiring an additional 62,790 shares during the last quarter. VELA Investment Management LLC increased its position in Thermo Fisher Scientific by 65.5% during the third quarter. VELA Investment Management LLC now owns 9,305 shares of the medical research company's stock valued at $4,513,000 after acquiring an additional 3,683 shares during the last quarter. Finally, NEOS Investment Management LLC increased its position in Thermo Fisher Scientific by 28.6% during the third quarter. NEOS Investment Management LLC now owns 51,364 shares of the medical research company's stock valued at $24,913,000 after acquiring an additional 11,415 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Price Performance

NYSE:TMO opened at $448.34 on Wednesday. The company has a current ratio of 1.53, a quick ratio of 1.15 and a debt-to-equity ratio of 0.77. The company has a market capitalization of $166.61 billion, a P/E ratio of 24.65, a P/E/G ratio of 1.96 and a beta of 0.88. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $643.99. The business's 50-day moving average is $483.39 and its 200 day moving average is $540.37.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, topping analysts' consensus estimates of $5.25 by $0.19. The company had revenue of $11.01 billion for the quarter, compared to the consensus estimate of $10.86 billion. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The firm's revenue for the quarter was up 6.2% on a year-over-year basis. During the same period in the previous year, the business earned $5.15 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 24.86 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, April 15th. Shareholders of record on Friday, March 13th were given a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.43. The ex-dividend date was Friday, March 13th. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 10.34%.

Insider Buying and Selling

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 5,000 shares of the company's stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the sale, the chief executive officer directly owned 123,925 shares in the company, valued at $63,499,170. This represents a 3.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, COO Gianluca Pettiti sold 400 shares of the company's stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the sale, the chief operating officer owned 25,051 shares in the company, valued at approximately $11,590,095.66. This trade represents a 1.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.33% of the company's stock.

Analyst Ratings Changes

TMO has been the subject of a number of research reports. Robert W. Baird reduced their price objective on Thermo Fisher Scientific from $653.00 to $639.00 and set an "outperform" rating for the company in a research report on Friday, April 24th. Stifel Nicolaus cut their price target on Thermo Fisher Scientific from $700.00 to $600.00 and set a "buy" rating for the company in a report on Friday, April 24th. UBS Group reissued a "neutral" rating and set a $615.00 price target on shares of Thermo Fisher Scientific in a report on Friday, January 30th. Weiss Ratings reissued a "hold (c)" rating on shares of Thermo Fisher Scientific in a report on Wednesday, April 8th. Finally, Morgan Stanley reissued an "overweight" rating and set a $620.00 price target on shares of Thermo Fisher Scientific in a report on Monday, April 27th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, Thermo Fisher Scientific has a consensus rating of "Moderate Buy" and a consensus target price of $616.10.

About Thermo Fisher Scientific

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.